Hess Midstream LP (HESM)

Hess Midstream LP recently reported past first-quarter 2026 results, posting higher year-over-year revenue of US$390.1 million and net income of US$87.6 million, alongside steady operational throughput across most segments. The company also reaffirmed its full-year 2026 net income outlook of ...

Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.

Hess Midstream (HESM) opened 2026 earnings season with Q1 results that sit against a backdrop of 2025 revenue between US$382 million and US$420.9 million per quarter and basic EPS ranging from US$0.65 to US$0.75, with trailing 12 month revenue at US$1.62 billion and basic EPS of US$2.87.

Market Analysis by covering: Novo Nordisk A/S, Hims Hers Health Inc. Read 's Market Analysis on Investing.com

Hims & Hers Health posted Q1 2026 results on May 21, 2026, with revenue of $608.1M missing analyst estimates. A strategic pivot from compounded to branded weight loss products caused near-term margin pressure, though full-year revenue guidance was raised to $2.9B.